N-(1-piperidinyl)isobutyramide | 925037-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-piperidinyl)isobutyramide
• 英文别名: 2-methyl-N-piperidin-1-ylpropanamide
• CAS: 925037-37-2
• 化学式: C₉H₁₈N₂O
• mdl: MFCD08714874
• 分子量: 170.255
• InChiKey: PIJXEXUJBCZVAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  NiCl2*2 acetonitrile 、 N-(1-piperidinyl)isobutyramide 在 potassium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以11%的产率得到
  参考文献：
  名称：

  Exceptional thermal stability and high volatility in mid to late first row transition metal complexes containing carbohydrazide ligands

  摘要：

  Treatment of metal(II) halides (metal = Cu, Ni, Co, Fe, Mn, Cr) with the potassium salts of carbohydrazides L-1-L-6 afforded Cu(L-1)(2) (75%), Cu(L-2)(2) (51%), Cu(L-3)(2) (23%), Co(L-1)(2) (57%), Cr(L-1)(2) (62%), Ni(L-1)(2) (76%), Ni(L-2)(2) (62%), Ni(L-3)(2) (62%), Ni(L-4)(2) (13%), Ni(L-5)(2) (11%), Ni(L-6)(2) (29%), [Fe(L-1)(2)](2) (28%), and [Mn(L-1)(2)](2) (12%) as crystalline solids, where L-1 = Me2NN=C(tBu)O-, L-2 = Me2NN=C(iPr)O-, L-3 = Me2NN=C(Me)O-, L-4 = (CH2)(5)NN=C(tBu)O-, L-5 = (CH2)(5)NN=C(iPr)O-, and L-6 = (CH2)(5)NN=C(Me)O-. These complexes were characterized by spectral and analytical techniques, and by X-ray crystal structure determinations for Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), Ni(L-1)(2), and Fe(L-1)(2)](2). Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), and Ni(L-1)(2) exist as square planar, monomeric complexes, whereas [Fe(L1)2]2 is a dimer. A combination of sublimation studies, thermal decomposition temperature determinations, and thermogravimetric/differential thermal analysis demonstrate that the Cu, Co, and Ni complexes Cu(L-1)(2), Cu(L-2)(2), Co(L-1)(2), Ni(L-1)(2), and Ni(L-2)(2) have the lowest sublimation temperatures and highest decomposition temperatures among the series. Additionally, these compounds have higher volatilities and thermal stabilities than commonly used ALD and CVD precursors. Hence, these new complexes have excellent properties for application as ALD precursors to Cu, Co, and Ni metal films. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.07.034
• 作为产物：
  描述：

  1-氨基哌啶 、 异丁酰氯 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 17.0h， 生成 N-(1-piperidinyl)isobutyramide
  参考文献：
  名称：

  Exceptional thermal stability and high volatility in mid to late first row transition metal complexes containing carbohydrazide ligands

  摘要：

  Treatment of metal(II) halides (metal = Cu, Ni, Co, Fe, Mn, Cr) with the potassium salts of carbohydrazides L-1-L-6 afforded Cu(L-1)(2) (75%), Cu(L-2)(2) (51%), Cu(L-3)(2) (23%), Co(L-1)(2) (57%), Cr(L-1)(2) (62%), Ni(L-1)(2) (76%), Ni(L-2)(2) (62%), Ni(L-3)(2) (62%), Ni(L-4)(2) (13%), Ni(L-5)(2) (11%), Ni(L-6)(2) (29%), [Fe(L-1)(2)](2) (28%), and [Mn(L-1)(2)](2) (12%) as crystalline solids, where L-1 = Me2NN=C(tBu)O-, L-2 = Me2NN=C(iPr)O-, L-3 = Me2NN=C(Me)O-, L-4 = (CH2)(5)NN=C(tBu)O-, L-5 = (CH2)(5)NN=C(iPr)O-, and L-6 = (CH2)(5)NN=C(Me)O-. These complexes were characterized by spectral and analytical techniques, and by X-ray crystal structure determinations for Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), Ni(L-1)(2), and Fe(L-1)(2)](2). Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), and Ni(L-1)(2) exist as square planar, monomeric complexes, whereas [Fe(L1)2]2 is a dimer. A combination of sublimation studies, thermal decomposition temperature determinations, and thermogravimetric/differential thermal analysis demonstrate that the Cu, Co, and Ni complexes Cu(L-1)(2), Cu(L-2)(2), Co(L-1)(2), Ni(L-1)(2), and Ni(L-2)(2) have the lowest sublimation temperatures and highest decomposition temperatures among the series. Additionally, these compounds have higher volatilities and thermal stabilities than commonly used ALD and CVD precursors. Hence, these new complexes have excellent properties for application as ALD precursors to Cu, Co, and Ni metal films. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.07.034

文献信息

• [EN] COMPOUNDS FOR TREATING INFECTIONS CAUSED BY RIFAMPICIN-RESISTANT BACTERIA<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS PROVOQUÉES PAR DES BACTÉRIES RÉSISTANTES À LA RIFAMPICINE
  申请人：DEMURIS LTD

  公开号：WO2020021252A1

  公开（公告）日：2020-01-30

  Novel compounds of formulae (l)-(lll) are provided, as well as pharmaceutical compositions comprising the novel compounds. Also described are therapeutic uses of the novel compounds, in particular in relation to the treatment of infections caused by rifampicin- resistant bacteria, e.g. rifampicin-resistant tuberculosis.

  提供了公式（l）-（lll）的新化合物，以及包含这些新化合物的药物组合物。还描述了新化合物的治疗用途，特别是与治疗由利福平耐药细菌引起的感染有关，例如利福平耐药结核病。